Kyverna's Miv-cel Shows Durable Benefits in Stiff Person Syndrome Trial
Event summary
- Kyverna's KYSA-8 trial of miv-cel in stiff person syndrome (SPS) met all primary and secondary endpoints, showing statistically significant improvements in mobility and disability.
- A single dose of miv-cel led to a 46% median improvement in the Timed 25-Foot Walk (T25FW) at 16 weeks, with 81% of patients achieving clinically meaningful improvement.
- All 26 patients discontinued chronic immunotherapies, and miv-cel was well-tolerated with no high-grade cytokine release syndrome or neurotoxicity observed.
- Kyverna plans to submit a Biologics License Application (BLA) for miv-cel in SPS, positioning it as a potential first-approved treatment for the disease.
The big picture
Kyverna's positive KYSA-8 trial results position miv-cel as a potential game-changer in the treatment of stiff person syndrome, a rare and debilitating autoimmune disease. The durable benefits observed with a single dose highlight the potential of cell therapy to reset the immune system and provide long-term remission. This success could pave the way for miv-cel's approval in SPS and expansion into other autoimmune indications, reinforcing Kyverna's leadership in cell therapy for autoimmune diseases.
What we're watching
- Regulatory Pathway
- Whether Kyverna's BLA submission for miv-cel in SPS will be expedited given the unmet need and positive trial results.
- Market Potential
- The pace at which miv-cel could capture market share in SPS, a rare disease with no approved treatments.
- Therapeutic Expansion
- How the success in SPS will influence Kyverna's development of miv-cel for other neurologic autoimmune diseases like myasthenia gravis.